A key part of the growth strategy for the Ted Rogers Centre for Heart Research is in establishing a team of chairs whose expertise and vision will help drive each aspect of the overall vision.

Loretta Rogers Chair in Immunobioengineering

Dr. Slava Epelman appointed April 2018

Goal: Catalyze existing research strengths and bring new expertise to solve unaddressed immunology-related problems in heart failure and regenerative cardiac therapy.

Ted Rogers Chair in Heart Function Outcomes

Dr. Douglas Lee appointed June 2016

Goal: Study how health policy, health system and patient factors affect the natural history and outcomes of individuals with heart failure. The Chair will exploit the unique cardiovascular database, disease modelling and systems biology capacity of the Ted Rogers Centre for Heart Research to inform their studies, integrate novel biological markers and available genetic markers into their analyses and formulate health policy advice.

Ted Rogers Chair in Cardiac Health Technology and Quality

Goal: Evaluate the many factors (behavioural, environmental, health policy and health systems) that affect the outcomes of individuals – or entire populations – with heart disease. In particular, the Chair will study and evaluate technologies such as new heart failure diagnostics and therapeutics (including new tests, drugs, cells, devices, or programs of care) developed by the Ted Rogers Centre for Heart Research. The chair will also evaluate the many highly advanced technologies and medical devices already deployed within the Peter Munk Cardiac Centre for the treatment of complex heart disease.

Ted Rogers Chair in Heart Function Biology

Goal: Provide leadership for the development and application of the unique computational capacity needed to perform systems biology-level analyses of the integrated cardiovascular database supported by the Ted Rogers Centre for Heart Research. This investigator will lead the acquisition and analysis of large, clinically linked data sets to inform how specific genetic, molecular, environmental, societal, and health systems factors drive the natural history and outcomes of heart failure. This critical analysis will inform the targeting of novel factors with new diagnostic, therapeutic or health systems approaches.

Ted Rogers Chair in Translational Genomics

Goal: Translate genome information into a mechanistic understanding of gene defects and lead the development of new cell or developmental-based screens for novel therapeutic interventions in congenital heart disease.

Ted Rogers Chair in Cardiac Genetics

Goal: Direct research that is designed to increase understanding of the links between specific genes and heart disease development. By studying the genomes of patients at UHN and SickKids, we will be able to identify people at risk for heart failure before it develops.


Ted Rogers Chair in Cardiac Tissue and Cellular Systems Modelling

Goal: Work closely with engineers, biologist and clinicians to generate predictive models of heart tissue functions that will guide therapeutic strategies. This regenerative medicine scientist or clinician scientist will lead the use of stem cells to make 3-D cardiovascular tissue constructs for the purpose of defining the physiological mechanisms of heart failure, and testing their reversibility with novel gene, drug or regenerative strategies.